# Selenium Hair Loss Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/selenium-hair-loss-randomized-trial-evidence-review
Category: evidence-review
Summary: Selenium Hair Loss Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are sys
Last reviewed: 2026-08-04
Reviewed by: Migaku Evidence Review
# Selenium Hair Loss Randomized Trial: What the Evidence Says

## Quick Answer

Selenium Hair Loss Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| The Impact of Selenium Exposure During Pregnancy on Risk for Miscarriage: A Systematic Review | systematic review | 1 | 2026-01-18 | 10.3390/ijms27020968 |
| Pharmacotherapeutic Interventions for Sensorineural Hearing Loss: A Scoping Review | narrative review | 3 | 2026-06-14 | 10.3390/audiolres16030091 |

## What The Sources Report

- Low Se levels are associated with increased risk of mortality, poor immune function, and cognitive decline. [Kyriakou Stavroula-Ioanna (2026); evidence level 1]
- In addition to its role in oxidative stress, GPx4 protects cells against ferroptosis, while its deficiency contributes to immune system dysregulation and increased inflammation. [Kyriakou Stavroula-Ioanna (2026); evidence level 1]
- Clinical trial records were excluded from this figure to avoid combining completed published evidence with ongoing or unpublished investigations. [Mavandi Matthew (2026); evidence level 3]
- The ACCL0431 study and the SIOPEL-6 trial both demonstrated that delayed infusion of STS significantly reduced the incidence and severity of cisplatin-induced hearing loss in pediatric patients. [Mavandi Matthew (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For selenium hair loss randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Kyriakou Stavroula-Ioanna (2026). The Impact of Selenium Exposure During Pregnancy on Risk for Miscarriage: A Systematic Review. DOI: 10.3390/ijms27020968. PMCID: PMC12842137. PMID: 41596613. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12842137/
- Mavandi Matthew (2026). Pharmacotherapeutic Interventions for Sensorineural Hearing Loss: A Scoping Review. DOI: 10.3390/audiolres16030091. PMCID: PMC13295749. PMID: 42345630. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13295749/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.